Company Overview and News

6
Expected Value Investing:  Analyzing Genfit's Huge Potential

17h seekingalpha
Alongside Intercept, Genfit is the leader in the NASH fibrosis race - it is currently conducting a Phase 3 trial evaluating its lead drug candidate elafibranor (readout expected in 2019).
MDGL GLMD GNFTF ICPT VKTX

78
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis

2018-10-02 zacks - 3
Chicago, IL – October 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Champions Oncology, Inc. (CSBR - Free Report) , CytoDyn Inc. (CYDY - Free Report) , Infinity Pharmaceuticals, Inc. (INFI - Free Report) , Nektar Therapeutics (NKTR - Free Report) and Zoetis Inc.
NKTR STZ.B MDGL GILD COST SRPT WTW ZTS STZ VKTX SFIX AMRN INFI ACAD VKTXW CYDY CSBR ALXN KWR LULU FSLR

58
5 Best Biotech Stocks to Buy In October

2018-10-01 zacks - 8
October traditionally has been a weak month for stocks. However, biotech stocks have shown significant resilience so far this year, with the iShares Nasdaq Biotechnology ETF (IBB) gaining 11.5% year-to-date (YTD). Additionally, the broader Health Care Select Sector SPDR ETF (XLV) has risen 15.1% YTD, better than the S&P 500’s increase of 9% during the same period.
NKTR MDGL GILD SRPT VKTX ZTS AMRN INFI ACAD VKTXW 2454 CYDY AGN ALXN CSBR

22
Movers and Shakers Oct. 1

2018-10-01 biospace - 3
Second Genome -- South San Francisco-based Second Genome tapped Chief Scientific Officer Karim Dabbagh as its new president and chief executive officer. Dabbagh will replace Glenn Nedwin, who retired from the company. Prior to Second Genome, Dabbagh served as head of the immunoregulation department and external R&D innovation for autoimmune and inflammatory diseases at Pfizer. Before Pfizer, Dabbagh co-founded Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease.
ACAD MDGL AMAG XLRN SNTA JUNO RARX FOLD QSII DRNA AERI ARRY

26
5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

2018-09-27 investorplace - 3
The stars are aligning for several biotech stocks. Thirty-five billion stars in fact. That huge number in dollars represents the potential annual spending needed to treat one of the biggest and growing problems facing the healthcare sector today. We’re talking about NASH.
MDGL GILD GALTW GALTU ICPT VKTX GALT BMY

4
Viking Therapeutics And VK2809: The Hype On NASH

2018-09-26 seekingalpha - 3
VK2809 is a promising thyroid hormone receptor β-selective agonist in early phase clinical trial for metabolic disorders.
MDGL VKTXW VKTX

5
Is NASH Really a $35 Billion Opportunity?

2018-09-26 biospace - 1
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize?
TBRA MDGL VKTXW GILD ICPT VKTX

1
Moving The Chains On Viking Therapeutics

2018-09-20 seekingalpha
Viking Therapeutics (NASDAQ:VKTX) threw quite the pass this week for a first down. It was NAFLD data that was, at the least, comparable to its direct future competitor: Madrigal Pharmaceuticals (MDGL).
MDGL VKTXW LGND VKTX

4
Viking Is A Biotech With Massive Potential

2018-09-19 seekingalpha
Viking Therapeutics announces that both the primary and secondary endpoints of its phase 2 NASH study were met.
MDGL VKTXW ICPT VKTX

4
Viking Therapeutics Liver Candidate Passes Test, Shares Soar

2018-09-19 zacks
Shares of Viking Therapeutics Inc. soared more than 87% yesterday on favorable top-line data from a phase II study, evaluating its novel liver-selective thyroid receptor beta agonist, VK2809, for treating non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
MDGL VKTXW AGN GILD CNAT ICPT VKTX

1
Viking Therapeutics stock up after promising results for fatty liver drug

2018-09-18 sfgate
Shares of Viking Therapeutics soared 87 percent Tuesday to close at $19.46 after the company said initial results for an experimental therapy for fatty liver disease exceeded investors’ expectations.
MDGL VKTXW VKTX

2
Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

2018-09-18 marketwatch - 1
Viking just announced positive midstage trial results, and has more news planned for release this fall
MDGL VKTXW VKTX

3
NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data

2018-09-18 biospace
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). Company shares blasted 140 percent in premarket trading at the news.
MDGL GILD ICPT

2
Viking shares soar as liver disease drug succeeds in mid-stage study

2018-09-18 channelnewsasia - 1
REUTERS: Viking Therapeutics Inc's shares more than doubled on Tuesday after its experimental liver disease treatment met the goals of a mid-stage trial by lowering cholesterol and liver fat levels in patients.
MDGL VKTXW VKTX

20
Your Daily Pharma Scoop: Viking's Data Readout, Alpelisib Succeeds, Shire Receives Approval

2018-08-25 seekingalpha - 4
Discussion: Share price of Viking Therapeutics (VKTX) has moved up 7% on average volume ahead of mid-stage data readout of its candidate VK2809. The anticipated trial data is indicated in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). The candidate has a similar mechanism to Madrigal’s (NASDAQ:MDGL) MGL-3196. Viking had a June breakout connected to Madrigal’s successful mid-stage trial results.
NTLA MDGL DTHR AZN KRYS VKTX KNMXD SHPG VKTXW AVGR KALA MRK CELG NVS ADVM MNK DCTH DCTHD BMY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MDGL / Madrigal Pharmaceuticals, Inc. on message board site Silicon Investor.

Madrigal Pharmaceuticals Madrigal Pharmaceuticals Madrigal Pharmaceuticals
CUSIP: 87162T206